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Research
A MAJOR FEATURE of hepatitis C virus
(HCV) infection is the highly variable
course of its natural history. Although
most people develo  chronic infection,
with its consequent risk of cirrhosis,
liver failure and hepatocellular carci-
noma, only a minority will progress to
these advanced liver disease endpoints.1
A key question is whether patients at
high risk of disease progression can be
distinguished from those with a rela-
tively benign disease course.
Factors previously shown to influence
disease progression in chronic hepatitis C
have included duration of infection, age at
infection, sex, alcohol intake, and co-
infection with HIV and hepatitis B virus
(HBV).2-6 Evidence about the role of
other factors, such as source of HCV
infection and ethnicity, is less clear. People
with chronic HCV infection and persist-
ently normal serum transaminase levels
are less likely to progress to advanced liver
disease than those with abnormal levels.7
However, there is conflicting evidence as
to the importance of serum transaminase
levels in predicting progression among
those with abnormal levels.8-10
Consensus guidelines for managing
chronic HCV infection generally recom-
mend antiviral therapy for people with
moderate to severe hepatic fibrosis, while
often recommending observation of peo-
ple in whom fibrosis is either absent or
minimal.11 Thus, correlates of hepatic
fibrosis severity could be used to develop
assessment and monitoring strategies for
chronic HCV infection, including selec-
tion of patients for liver biopsy and possi-
ble therapeutic intervention.
To assess factors that may influence
the development of hepatic fibrosis, we
analysed pretreatment demographic
and clinical data for patients receiving




In Australia, interferon therapy became
available under the Pharmaceutical Ben-
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ABSTRACT
Objective:  To determine factors associated with hepatic fibrosis development in 
people with chronic hepatitis C virus (HCV) infection.
Methods:  As a requirement for access to interferon therapy through the S100 scheme 
in Australia, individual pretreatment demographic and clinical information was collected 
on 2986 patients from 61 hospital-based liver clinics from 1 October 1994 through 31 
December 1996. Patients with both a hepatic fibrosis score and an estimated duration 
of HCV infection (910) were divided into 540 with no or minimal hepatic fibrosis (stage 
0–1) and 370 with moderate to severe hepatic fibrosis (stage 2–3). Seven factors were 
examined: age at HCV infection, sex, ethnicity, source of infection, duration of infection, 
alcohol intake, and mean ALT level. A further analysis was performed for all 1135 
patients with a hepatic fibrosis score disregarding age at and duration of HCV infection.
Results:  In multivariate analysis, four factors were significantly associated with 
moderate to severe hepatic fibrosis: age at infection (OR, 2.33 for age 31–40 years, 
5.27 for age >40 years, and 0.20 for age <15 years, compared with 15–20 years); 
duration of infection (OR, 1.44 for 11–20 years, 2.74 for 21–30 years, and 8.71 for >30 
years, compared with <11 years); alcohol intake in previous six months (OR, 1.51 for 
any intake, compared with none); and mean ALT level (OR, 1.81 for 2–3 times, 2.27 
for >3 times, compared with 1.5–2 times the upper limit of normal). In the analysis 
disregarding age at HCV infection and duration of HCV infection, older age was 
strongly associated with moderate to severe hepatic fibrosis (OR, 2.32 for age 36–40 
years, 2.46 for age 41–50 years, 7.87 for age 51–60 years, and 7.15 for age >60 years, 
compared with 16–30 years). There was no association in either analysis with sex or 
source of HCV infection.
Conclusion:  These factors may assist in targeting patients for both liver biopsy-based 
MJA 2002; 177: 240–245
investigation and therapeutic intervention.
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infection in 1994. Approved doctors
practising in public hospital-based clinics
could prescribe interferon therapy
through the S100 scheme, which pro-
vides access to restricted therapies.
Access to S100 interferon therapy
required that individual pretreatment
information was recorded and forwarded
to a database established at the John
Hunter Hospital, Newcastle. Access to
S100 interferon during the study period
also required confirmation of chronic
hepatitis C by a positive HCV antibody
test result on two occasions, and histo-
logical evidence of chronic hepatitis.
Alanine aminotransferase (ALT) levels
had to be elevated more than 1.5 times
the upper limit of normal (ULN) on
three occasions in the six months before
beginning interferon therapy. Patients
with HIV, other causes of chronic liver
disease and established cirrhosis were
excluded from receiving interferon
through the S100 scheme.
Information was available on patients
receiving S100 interferon therapy
between 1 October 1994 and 31 Decem-
ber 1996 at 61 hospitals in all Australian
States and Territories (Australian Capi-
tal Territory, 1; New South Wales, 22;
Northern Territory, 2; Queensland, 9;
South Australia, 6; Tasmania, 3; Victo-
ria, 12; Western Australia, 6; full list
available from the authors). Baseline
(pretreatment) information was recorded
by doctors on standardised forms and
forwarded to the S100 database coordi-
nator. Demographic (age, sex, country of
birth, and ethnicity) and clinical (source
of infection, estimated time of exposure,
ALT levels, alcohol intake, and liver
biopsy findings) variables were included.
Data on hepatitis B virus serology, HCV
genotype and HCV viral load were only
available for a minority of patients.
Histopathological findings from liver
biopsies performed in the six months
before baseline assessment were
recorded. Portal/periportal and lobular
inflammatory activity and staging of
fibrosis were generally graded on a five-
point (0–4) scoring system according to
Scheuer.12 Histopathological classifica-
tion systems in which the denominator
for fibrosis was greater than four were
used in some cases, but these patients
were excluded from the analyses.
We performed analyses to examine
factors which might distinguish
patients with moderate to severe
hepatic fibrosis (stage 2–3) from those
with no or minimal hepatic fibrosis
(stage 0–1). The fibrosis scores were
grouped in this way, as consensus
guidelines now generally recommend
antiviral therapy for patients with mod-
erate to severe hepatic fibrosis.11
Patients with stage 4 fibrosis (cirrhosis)
were not eligible for S100 interferon
therapy, and were excluded.
Seven variables were initially examined
among the subgroup of patients with a
fibrosis score of 0–3 and a recorded
estimated duration of HCV infection.
These were age at infection, sex, ethnic-
ity, source of infection, duration of infec-
tion, alcohol intake, and mean ALT
level. Duration of infection was defined
as the time interval between estimated
time of exposure and date of liver biopsy.
1: Baseline demographic and clinical characteristics of patients with 
known and unknown hepatic fibrosis scores






Age at biopsy (years) <0.0005
16–30 161 (14.2%) 299 (18.2%) 460 (16.6%)
31–40 537 (47.3%) 802 (48.9%) 1339 (48.3%)
41–50 292 (25.7%) 343 (20.9%) 635 (22.9%)
51–60 98 (8.6%) 77 (4.7%) 175 (6.3%)
60+ 44 (3.9%) 38 (2.3%) 83 (3.0%)
Unknown 3 (0.3%) 81 (4.9%) 84 (3.0%)
Sex 0.41
Male 775 (68.3%) 1144 (69.8%) 1919 (69.2%)
Female 360 (31.7%) 496 (30.2%) 856 (30.8%)
Ethnicity <0.0005
Asian 181 (15.9%) 135 (8.2%) 316 (11.4%)
Caucasian 911 (80.3%) 1459 (89.0%) 2370 (85.4%)
Other 41 (3.6%) 39 (2.4%) 80 (2.9%)
Unknown 2 (0.2%) 7 (0.4%) 9 (0.3%)
Source of infection <0.0005
Blood product 153 (13.5%) 282 (17.2%) 435 (15.7%)
IDU 600 (52.9%) 976 (59.5%) 1576 (56.8%)
COBHP 168 (14.8%) 124 (7.6%) 292 (10.5%)
Tattoo 57 (5.0%) 64 (3.9%) 121 (4.4%)
Other 70 (6.2%) 96 (5.9%) 166 (6.0%)
Unknown 87 (7.7%) 98 (5.9%) 185 (6.7%)
Duration of infection (years) 0.015
<11 249 (21.9%) 390 (23.8%) 639 (23.0%)
11–20 436 (38.4%) 658 (40.1%) 1094 (39.4%)
21–30 158 (13.9%) 209 (12.7%) 367 (13.2%)
>30 67 (5.9%) 58 (3.5%) 125 (4.5%)
Unknown 225 (19.8%) 325 (19.8%) 550 (19.8%)
Alcohol intake in the previous six months 0.003
No 514 (45.3%) 921 (56.2%) 1435 (51.7%)
Yes 474 (41.8%) 667 (40.7%) 1141 (41.1%)
Unknown 147 (12.9%) 52 (3.1%) 199 (7.2%)
Mean ALT level (x upper limit of normal) 0.26
1.5–2 211 (18.6%) 299 (18.2%) 510 (18.4%)
>2–3 343 (30.2%) 482 (29.4%) 825 (29.7%)
>3 519 (45.7%) 640 (39.0%) 1159 (41.8%)
Unknown 62 (5.5%) 219 (13.4%) 281 (10.1%)
IDU=injecting drug use; COBHP=country of birth high prevalence; ALT=alanine aminotransferase.
*For comparison of known and unknown fibrosis groups.
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Alcohol intake was estimated from the
recorded mean consumption in the pre-
vious six months. Mean ALT was calcu-
lated from three ALT measurements
carried out within six months of the liver
biopsy, and expressed as a multiple of
ULN for the particular laboratory.
As duration of HCV infection is often
difficult to assess, a second analysis was
performed to examine factors associated
with hepatic fibrosis in the absence of
duration of infection. We analysed six
variables for all patients with a hepatic
fibrosis score of 0–3, whether or not
there was an estimated duration of infec-
tion. These variables were age at liver
biopsy, sex, ethnicity, source of infection,
alcohol intake, and mean ALT level.
For both analyses univariate and mul-
tivariate models were used to examine
associations between selected variables
and hepatic fibrosis score. In univariate
analyses 2 tests were used to examine
categorical variables. All selected varia-
bles were entered into a multivariate
logistic regression model to examine
independent associations.
Finally, we assessed the relationship
between hepatic fibrosis score and both
mean ALT level and inflammatory score
(portal/periportal, lobular, and com-
bined) using a Wilcoxon-type test for
trend.13 Values were considered statisti-
cally significant if the P value was < 0.05




Over the 26 months, we recruited 2986
patients from 61 hospitals. Most came
from New South Wales (1314) and Vic-
toria (638). However, the numbers from
the other States and Territories were in
approximate proportion to their popula-
tions. Patients who had previously
received interferon therapy (172) and
those in whom a clearly different histo-
logical scoring system was used (39)
were excluded from the original study
population.
Among the remaining 2775 patients,
69% were male and the median age at
liver biopsy was 37 years. The most
common sources of HCV exposure were
a history of injecting drug use (IDU)
(56.8%) and transfusion of blood prod-
ucts (15.7%). An additional 10.5% were
born in a country of relatively high back-
ground HCV prevalence, and 6.7% had
an unknown source. After Australia
(71.2%), the most common countries or
regions of birth were Vietnam (8.2%),
Europe (6.1%) and other South-East
Asian countries (3.6%). Ethnicity was
recorded as “white” for 85.4%, “Asian”
for 11.4%, and “other” in 2.9% of cases.
Individual fibrosis scores were
recorded in 1135 patients (40.9%).
Among these, the distribution of hepatic
fibrosis score was 0 (22.1%), 1 (37.3%),
2 (27.8%), and 3 (12.9%). Patients with
and without a fibrosis score are com-
pared in Box 1. There was a higher
proportion of Asian patients and those
with a high HCV prevalence in their
country of birth as their source of infec-
tion in the group with known fibrosis
scores.
Both an individual hepatic fibrosis score
of 0–3 and estimated duration of infection
were available for 910 patients (32.8%),
who were therefore included in the first
analysis of factors associated with hepatic
2: Factors associated with moderate to severe hepatic fibrosis (fibrosis 
score, 2–3) in patients with an estimated age at HCV infection
Fibrosis score 
0–1 (n = 540)
Fibrosis score
2–3 (n = 370) OR 95% CI
Age at infection (years)
<15 67 (12.4%) 31 (8.4%) 0.20* 0.09–0.46
15–20 205 (38.0%) 147 (39.7%) 1.00
21–30 216 (40.0%) 124 (33.5%) 0.91 0.66–1.27
31–40 41 (7.6%) 45 (12.2%) 2.33* 1.38–3.92
>40 11 (2.0%) 23 (6.2%) 5.27* 2.32–11.94
Sex
Male 358 (66.3%) 269 (72.7%) 1.00
Female 182 (33.7%) 101 (27.3%) 0.79 0.58–1.09
Ethnicity
Asian 47 (8.7%) 34 (9.2%) 1.00
White 483 (89.4%) 320 (86.5%) 1.07 0.53–2.16
Other 9 (1.7%) 15 (4.0%) 2.64 0.90–7.73
Unknown 1 (0.2%) 1 (0.3%) 1.48 0.08–27.45
Source of infection
Blood product 76 (14.1%) 72 (19.5%) 1.00
IDU 355 (65.7%) 225 (60.8%) 0.95 0.60–1.49
COBHP 37 (6.9%) 25 (6.8%) 0.76 0.27–2.18
Tattoo 29 (5.4%) 23 (6.2%) 1.02 0.50–2.10
Other 33 (6.1%) 19 (5.1%) 0.79 0.39–1.59
Unknown 10 (1.8%) 6 (1.6%) 0.80 0.24–2.62
Duration of infection (years)
<11 155 (28.7%) 94 (25.4%) 1.00
11–20 267 (49.4%) 169 (45.7%) 1.44 1.00–2.06
21–30 81 (15.0%) 77 (20.8%) 2.74* 1.70–4.41
>30 37 (6.9%) 30 (8.1%) 8.71* 3.32–22.80
Alcohol intake in the previous six months
No 247 (45.7%) 151 (40.8%) 1.00
Yes 222 (41.1%) 175 (47.3%) 1.51* 1.11–2.05
Unknown 71 (13.2%) 44 (11.9%) 1.21 0.75–1.96
Mean ALT level (x upper limit of normal)
1.5–2 121 (22.4%) 52 (14.1%) 1.00
>2–3 154 (28.5%) 115 (31.1%) 1.81* 1.18–2.76
>3 224 (41.5%) 194 (52.4%) 2.27* 1.52–3.39
Unknown 41 (7.6%) 9 (2.4%) 0.46 0.20–1.07
OR=adjusted odds ratio; IDU=injecting drug use; COBHP=country of birth high prevalence; 
ALT=alanine aminotransferase. *Significant at P< 0.05.
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fibrosis. In univariate analysis, age at
infection, mean ALT level and sex were
associated with hepatic fibrosis score. In
multivariate analysis, moderate to severe
hepatic fibrosis was associated with older
age at infection, longer duration of infec-
tion, higher mean ALT level, and alcohol
intake in the previous six months (Box 2).
A comparison of patients with and
without estimated duration of infection is
shown in Box 3. Patients without esti-
mated duration of infection were older,
more likely to be Asian, and to have a
high HCV prevalence in their country of
birth as their source of infection. How-
ever, there was no significant difference
in sex, mean ALT level and fibrosis score
between these two groups.
The analysis of predictors of hepatic
fibrosis among all 1135 patients with a
fibrosis score, omitting the duration of
HCV infection (and age at infection)
variable, but including age at liver
biopsy, is shown in Box 4. In univariate
analysis, age at liver biopsy, ethnicity,
and mean ALT level were associated
with hepatic fibrosis score. In multivari-
ate analysis, moderate to severe hepatic
fibrosis was associated with age at biopsy
greater than 35 years, “other” ethnicity,
alcohol intake in the previous six
months, and higher mean ALT level. As
ALT data were from many different lab-
oratories, we repeated the analyses
reported in Boxes 2 and 4 using absolute
ALT groupings rather than times the
upper limit of normal, but the significant
associations were unchanged (data not
shown).
There was a significant positive rank
correlation between the hepatic fibrosis
score and both the portal/periportal and
lobular measures of inflammatory activ-
ity. However, the correlation was greatest
for portal/periportal activity (Box 5).
Although statistically significant, the cor-
relation between mean serum ALT level
and hepatic fibrosis score was weaker




Current antiviral therapy guidelines
strongly recommend therapeutic inter-
vention for patients who have developed
moderate to severe hepatic fibrosis,11 as
the risk of progression to advanced liver
disease is relatively high in this group.14
Our study suggests that, in chronic HCV
infection, more severe hepatic fibrosis is
associated with older age at infection,
longer duration of infection, alcohol
intake, and higher ALT levels. In con-
trast, sex, ethnicity and source of infec-
tion did not influence the extent of
hepatic fibrosis.
There were several limitations in our
methods. First was the use of cross-
sectional data to examine a longitudinal
process. Cross-sectional analyses rely on
estimation of time of HCV exposure,
which is often problematic. To help
counter this, we analysed separately
patients in whom hepatic fibrosis score
and time of HCV exposure were
recorded, and all patients with hepatic
fibrosis score with no regard to time of
HCV exposure. Secondly, a large pro-
portion of patients did not have a hepatic
fibrosis score recorded, and there were
differences in demographic and clinical
characteristics between patients with and
without a fibrosis score. Thirdly, being
based on liver clinic populations, the
participants were probably not totally
3: Baseline demographic and clinical characteristics among patients with 
and without estimated duration of infection
Known duration of
infection (n=2225)
Unknown duration of 
infection  (n=550) P
Age at biopsy (years) <0.0005
16–30 414 (18.6%) 46 (8.4%)
31–40 1157 (52.0%) 182 (33.1%)
41–50 512 (23.0%) 123 (22.4%)
51–60 97 (4.4%) 78 (14.2%)
60+ 45 (2.0%) 37 (6.7%)
Unknown 0 (0.0%) 84 (15.2%)
Sex 0.86
Male 1537 (69.1%) 382 (69.5%)
Female 688 (30.9%) 168 (60.5%)
Ethnicity <0.0005
Asian 141 (6.3%) 175 (31.8%)
Caucasian 2027 (91.1%) 343 (62.4%)
Other 50 (2.3%) 30 (5.4%)
Unknown 7 (0.3%) 2 (0.4%)
Source of infection <0.0005
Blood product 358 (16.1%) 77 (14.0%)
IDU 1508 (67.8%) 68 (12.4%)
COBHP 90 (4.0%) 202 (36.7%)
Tattoo 110 (5.0%) 11 (2.0%)
Other 125 (5.6%) 41 (7.5%)
Unknown 34 (1.5%) 151 (27.4%)
Alcohol intake in the previous six months 0.003
No 1126 (50.6%) 309 (56.1%)
Yes 949 (42.7%) 192 (35.0%)
Unknown 150 (6.7%) 49 (8.9%)
Mean ALT level (x upper limit of normal) 0.58
1.5–2 427 (19.1%) 83 (15.1%)
>2–3 674 (30.3%) 151 (27.5%)
>3 963 (43.3%) 196 (35.6%)
Unknown 161 (7.3%) 120 (21.8%)
Fibrosis score 0.58
0–1 540 (24.3%) 129 (23.4%)
2–3 370 (16.6%) 96 (17.5%)
Unknown 1315 (59.1%) 325 (59.1%)
IDU=injecting drug use; COBHP=country of birth high prevalence; ALT=alanine aminotransferase.
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representative of the Australian popula-
tion with hepatitis C. Finally, different
histopathological classification systems
for liver biopsy grading and staging were
used, but final analyses were limited to
patients whose fibrosis was staged under
a five-point scoring system.
A link between age at HCV infection
and the presence of hepatic fibrosis is
supported by the strong and consistent
trend of increasing risk with age at infec-
tion, and the independence of effect.
This relationship has been seen in several
previous cross-sectional studies.2,15,16
Some recent longitudinal studies have
found very low rates of progression to
advanced liver disease among young
adults infected through injecting drug
use and contaminated anti-D immuno-
globulin injections,17-19 and among
children infected through blood transfu-
sion.20 This association may also partly
explain the relatively more rapid disease
progression in adult post-transfusion
cohorts,21-24 as the median age at infec-
tion in these studies was generally 40–50
years.
We also found that duration of chronic
HCV infection was independently asso-
ciated with presence of hepatic fibrosis.
Again, such a finding is consistent with
other studies.1,2 The cross-sectional
nature of our study precludes examina-
tion of the possible non-linearity of dis-
ease progression, recently hypothesised
by others.25
Our study shows that age alone is an
important predictor of hepatic fibrosis
score. The risk of moderate to severe
hepatic fibrosis increased significantly
after 35 years of age in our study popula-
tion. This finding suggests that older
patients with chronic HCV infection and
abnormal ALT levels who are unable to
identify their time of HCV exposure
(and therefore their duration of infec-
tion) should strongly consider liver-
biopsy staging of disease.
Alcohol intake is often difficult to esti-
mate accurately, and consumption may
be modified after HCV infection is diag-
nosed. Current alcohol intake of less
than 70 g per week was also a require-
ment for access to interferon therapy. In
our study, alcohol intake in the previous
six months was not reported for many
patients, and only a small percentage
(3%) gave a history of heavy intake
(> 40 g/day). Despite this, alcohol intake
was associated with the presence of
hepatic fibrosis, as several other studies
have noted,2,26,27 although the increase
in the odds ratio was relatively small.
The relationship between serum
transaminase levels and risk of liver dis-
ease progression remains controversial.
Although risk of disease progression is
considerably higher among people with
abnormal serum transaminase levels
compared with those with consistently
normal levels,7 there is conflicting evi-
dence on the association between degree
of ALT abnormality and extent of histo-
logical fibrosis. Several studies have
shown either no correlation8,28,29 or a
very weak correlation30,31 between ALT
level and hepatic fibrosis. However, these
studies have had relatively small study
populations, with fewer than 100
patients undergoing liver biopsy. Our
findings suggest a “dose–response” pat-
tern for this relationship.
The pathogenesis of hepatic fibrosis in
chronic HCV infection is not well under-
stood; however, an association between
inflammatory activity and fibrogenesis is
likely. Progression to cirrhosis appears to
occur more commonly in patients with
chronic HCV infection and high-grade
necroinflammatory activity on liver
biopsy.32 Our findings suggest that portal/
periportal inflammatory activity may play




2–3 (n=466) OR 95% CI
Age at biopsy (years)
16–30 120 (17.9%) 41 (8.8%) 1.00
31–35 147 (22.0%) 77 (16.5%) 1.49 0.94–2.37
36–40 178 (26.6%) 135 (29.0%) 2.32* 1.50–3.60
41–50 168 (25.1%) 124 (26.6%) 2.46* 1.57–3.87
51–60 36 (5.4%) 62 (13.3%) 7.87* 4.22–14.70
>60 17 (2.5%) 27 (5.8%) 7.15* 3.25–15.74
Unknown 3 (0.5%) 0
Sex
Male 442 (66.1%) 333 (71.5%) 1.00
Female 227 (33.9%) 133 (28.5%) 0.86 0.65–1.14
Ethnicity
Asian 106 (15.8%) 75 (16.1%) 1.00
Caucasian 549 (82.1%) 362 (77.7%) 1.48 0.87–2.50
Other 13 (1.9%) 28 (6.0%) 4.74* 2.13–10.53
Unknown 1 (0.2%) 1 (0.2%) 2.18 0.13–37.81
Source of infection
Blood product 80 (12.0%) 73 (15.7%) 1.00
IDU 368 (55.0%) 232 (49.8%) 0.96 0.63–1.44
COBHP 91 (13.6%) 77 (16.5%) 0.91 0.50–1.65
Tattoo 32 (4.8%) 25 (5.4%) 1.07 0.55–2.09
Other 42 (6.3%) 28 (6.0%) 1.03 0.56–1.91
Unknown 56 (8.3%) 31 (6.6%) 0.56 0.31–1.01
Alcohol intake in the previous six months
No 312 (46.6%) 202 (43.4%) 1.00
Yes 266 (39.8%) 208 (44.6%) 1.35* 1.02–1.79
Unknown 91 (13.6%) 56 (12.0%) 1.11 0.74–1.67
Mean ALT level (x upper limit of normal)
1.5–2 144 (21.5%) 67 (14.4%) 1.00
>2–3 205 (30.6%) 138 (29.6%) 1.60* 1.09–2.34
>3 270 (40.4%) 249 (53.4%) 2.41* 1.67–3.46
Unknown 50 (7.5%) 12 (2.6%) 0.54 0.26–1.15
OR=adjusted odds ratio; IDU=injecting drug use; COBHP=country of birth high prevalence; ALT=alanine 
aminotransferase. *Significant at P <0.05.
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a more important role in fibrogenesis
than lobular activity. This finding is con-
sistent with the fact that the initial focus
of hepatic fibrosis is in the portal region.
This study adds to previous Australian
reports14,33,34 and contributes to a clearer
picture of the natural history of chronic
hepatitis C, particularly in the Australian
context. As patients with moderate to
severe hepatic fibrosis have a greatly
increased risk of progression to advanced
liver disease compared with those with
earlier stages of disease,14 the factors that
we have identified should improve our
ability to predict patients with progressive
disease. Patients with higher ALT levels,
longer duration of infection, older age,
and those who drink alcohol warrant spe-
cial attention, with more intensive follow-
up. These factors may also assist in target-
ing antiviral therapeutic intervention.
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5: Relationship between hepatic fibrosis score, necroinflammatory activity 





Mean inflammatory score Mean ALT 
level (x ULN)Portal/periportal Lobular Combined
0 222 1.4 1.3 2.7 3.2
1 368 1.7 1.5 3.2 3.6
2 257 2.1 1.7 3.8 3.9
3 126 2.5 1.8 4.3 4.1
P for trend <0.0005 <0.0005 <0.0005 <0.0005
Correlation  
coefficient 0.50 0.30 0.48 0.17
ALT=alanine aminotransferase; ULN=upper limit of normal. *Hepatic fibrosis on a five-point scoring system 
(patients with a score of 4 were excluded).
